Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial
Author:
Funder
Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
https://link.springer.com/content/pdf/10.1007/s10549-021-06216-5.pdf
Reference22 articles.
1. Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7–30
2. Mukai H (2010) Treatment strategy for HER2-positive breast cancer. Int J Clin Oncol 15(4):335–340
3. Cazzaniga ME, Biganzoli L, Cortesi L, De Placido S, Donadio M, Fabi A, Ferro A, Generali D, Lorusso V, Milani A et al (2019) Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future? Onco Targets Ther 12:2989–2997
4. Orlando L, Lorusso V, Giotta F, Di Maio M, Schiavone P, Fedele P, Quaranta A, Caliolo C, Ciccarese M, Cinefra M et al (2020) Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: a phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM). Breast (Edinburgh, Scotland) 53:18–22
5. Harbeck N, Gnant M (2017) Breast cancer. Lancet (London, England) 389(10074):1134–1150
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Optimizing cancer therapy: a review of the multifaceted effects of metronomic chemotherapy;Frontiers in Cell and Developmental Biology;2024-05-15
2. Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study;The Breast;2024-04
3. Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology;Heliyon;2024-02
4. Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial;The Breast;2023-12
5. Dose‐dependent bidirectional pharmacological effects of vinorelbine‐based metronomic combination chemotherapy on tumor growth and metastasis and mechanisms in melanoma mouse model;Fundamental & Clinical Pharmacology;2023-07-17
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3